Navigation Links
BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
Date:8/15/2013

Madison, WI (PRWEB) August 15, 2013

Methyltransferases are key players in epigenetic control of gene expression and have become the targets of intensive public and private drug discovery efforts. To accelerate these efforts, BellBrook developed the Transcreener EPIGEN Methyltransferase Assay, a fluorescent SAH detection assay with the sensitivity needed to detect any methyltransferase at physiological SAM concentrations, and the robustness required for industrial HTS. Since its introduction in 2011, the EPIGEN assay has been validated on all of the major instrument platforms and adopted by industrial and academic laboratories worldwide. Now, in response to customer feedback, we have reduced the number of components and simplified the protocol. The performance and response of the simplified assay is identical to the original kit; it contains pre-mixed detection components, so assay set-up is simpler and results are more reproducible.

By utilizing its expertise in HTS assay development, the BellBrook team is able to offer universal, fluorescence based detection of any methyltransferase enzyme that uses SAM as a methyl donor. This approach avoids the complexities and difficulties of detecting specific methylated products. The EPIGEN assay relies on enzymatic conversion of SAH to AMP, which is then detected using the Transcreener® AMP/GMP Assay. It provides robust activity measurements even with very low levels of SAM, while still offering the outstanding deck and signal stability of BellBrook’s Transcreener® Assays. Similar EPIGEN assays are being developed to screen additional epigenetic enzymes, including Histone Acetyltransferases (HATs).

About BellBrook Labs
BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11024850.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
2. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
3. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
4. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
5. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
6. 23andMe Launches First National TV Campaign
7. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
8. Dr. Gray Bailey Launches Ground Breaking Cavity Prevention Program That Can Lower Tooth Decay Rates by 74%
9. ASAE Launches New Book Guiding Association Professionals on How to Use Research for Results
10. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
11. SoundConnect Launches Innovative Partner Incentive Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Triumph Modular Incorporated, and manufacturing ... an international modular trade organization, were awarded First Place, as well as the ... Lab at Harvard University. The awards were presented at the 34th Annual World ...
(Date:3/28/2017)... , Belgium , March 28, 2017 /PRNewswire/ ... Limited (NYSE MKT: VNRX), today announced the engagement of ... Associates, LLC, as a strategic consultant. Dr. Vollmer Dahlke,s ... and securing non-dilutive funding in the State of ... States . Dr. Vollmer Dahlke has significant ...
(Date:3/28/2017)... 2017 Dr. Chris Yu , ... Anpac Bio-Medical Science Company , announced this ... processing and reporting over 40,000 cases worldwide of ... liquid biopsy tests. Described as ... publications, Anpac Bio,s CDA medical devices and technology ...
(Date:3/28/2017)... NC (PRWEB) , ... March 28, 2017 , ... ... side effects and diminished effectiveness over time. A recent study published in STEM ... PD by stimulating subventricular zone (SVZ) stem cells to produce more neural cells. ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
Breaking Biology News(10 mins):